Tag: Amgen

Abilita Bio and Amgen in Multi-Target Research Team

Abilita Bio, Inc. announced that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will lev...

CVS Added Teva and Lilly’s Drugs, Excluding Amgen’s

CVS Health Corp, a top U.S. manager of pharmacy benefits, has added new migraine drugs from Teva Pharmaceutical Industries and Eli Lilly and Co to its list of covered drugs, excluding a rival treatmen...

Expanded Indication from EC for Amgen’s Drug

Amgen announced that the European Commission (EC) has approved an expanded indication for BLINCYTO (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19...

Japan Approved Drug Rejected by FDA

Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the US...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...

FDA Approved sBLA for Nplate® for Pediatric Patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patie...

Amgen enters into research collaboration with Entera Bio

Entera Bio announced that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.

Amgen invests in Oxford Nanopore and its genetic sequencing technology

Amgen announced investment of $66 million in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology.

Amgen launches adalimumab biosimilar in Europe

Amgen announced that AMGEVITA, a biosimilar to adalimumab, to launch in markets across Europe. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).

Amgen will construct a next-generation biomanufacturing plant

The new plant is the first-of-its-kind in the USA and will use Amgen's proven next-generation biomanufacturing capabilities.

Amgen considers Turkey as a regional biopharmaceutical hub

The increase experienced in the domestic industry with the incentives issued by the government in a program with the pharmaceutical industry among primary strategic products, drew the attention of top pharma players to Turkey.

Biosimilar ABP 980 obtained a positive opinion from CHMP

cancer treatment
Amgen and Allergan have announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorisation of ABP 980, a biosimilar to Herceptin®.

Amgen will transfer technology for manufacturing of blinatumomab to Pharmstandard

Amgen and Pharmstandard announced the signing of an agreement on technology transfer, manufacturing and commercialization of blinatumomab in the Russian market